Philadelphia, Pennsylvania, USA, April 6, 2026
Optimized Phase 2 Design Targets Faster Clinical Development
In a strategic move to accelerate urology drug development, Medicus Pharma Ltd. has submitted an optimized Phase 2 clinical trial protocol to the U.S. FDA for its investigational GnRH antagonist Teverelix, targeting recurrent acute urinary retention (AURr) in patients with benign prostatic hyperplasia (BPH). The updated study design reflects a mechanism-driven and capital-efficient approach, aiming to generate rapid, decision-grade clinical data while significantly reducing development costs.
The refined protocol includes a target sample size of approximately 126 patients across the U.S. and Europe, representing a three-fold reduction compared to earlier designs, thereby improving execution speed and operational efficiency. With no currently approved pharmacologic therapies specifically addressing AUR recurrence, Teverelix is positioned to fill a major unmet medical need in a market estimated at $2 billion, highlighting its potential for commercial and clinical impact.
Mechanism-Driven Study Design Enhances Clinical Precision
The Phase 2 study (ANT-2111-02) incorporates a randomized, double-blind, four-arm design, evaluating both intramuscular (90 mg) and subcutaneous (120 mg) dosing of Teverelix against placebo controls. The study is anchored by a primary pharmacodynamic endpoint—percent change in total prostate volume (TPV) at Week 12, which is expected to provide a clear early signal of therapeutic activity. Secondary endpoints include maximum urine flow rate (Qmax), post-void residual volume (PVR), recurrence of AUR, and need for intervention, offering a comprehensive assessment of clinical benefit.
Advertisement
Notably, the trial includes a planned interim analysis at 50% patient completion, enabling early insights into dose optimization and future Phase 3 trial design, thereby enhancing development agility. Patients will receive a single injection followed by a 52-week evaluation period, ensuring both short-term and long-term outcomes are captured. This approach reflects a shift toward data-driven clinical strategies designed to accelerate regulatory pathways and improve success rates.
Addressing a Significant Unmet Need in Urology
Acute urinary retention is a serious complication of benign prostatic hyperplasia, often leading to hospitalization, catheterization, and increased risk of complications, with limited preventive treatment options available. Teverelix, as a next-generation GnRH antagonist, offers a novel therapeutic approach by targeting hormonal pathways involved in prostate enlargement, potentially reducing prostate volume and preventing recurrence of urinary retention episodes. The absence of approved pharmacologic treatments for AURr underscores the clinical urgency and market opportunity for innovative therapies like Teverelix.
The study is led by Dr. Steven A. Kaplan, a globally recognized expert in urology and men’s health, further strengthening the scientific rigor and credibility of the trial. By focusing on mechanism-based endpoints and streamlined study design, Medicus aims to deliver actionable clinical insights faster, supporting earlier strategic partnerships and commercialization pathways.
Advancing Precision-Driven Therapeutics Development
The submission of this optimized Phase 2 protocol highlights Medicus Pharma’s broader strategy of leveraging precision-guided clinical development and innovative trial design to accelerate time-to-market for novel therapeutics. Beyond Teverelix, the company is actively developing a pipeline of disruptive therapeutic assets, including SkinJect™, a localized immuno-oncology platform, and exploring AI-driven clinical analytics to enhance trial efficiency and patient selection. The Teverelix program exemplifies a modern, adaptive clinical development model, integrating pharmacodynamic insights, interim analyses, and cost-efficient design to maximize value creation.
As the company advances toward Phase 3 readiness and potential regulatory approval, Teverelix could emerge as a first-in-market therapy for preventing AUR recurrence, offering significant benefits to patients and healthcare systems worldwide. This milestone reinforces the growing importance of innovative trial design and precision medicine approaches in transforming drug development across therapeutic areas.
Source: Medicus Pharma press release
